Atossa Genetics (NASDAQ:ATOS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Atossa Genetics (NASDAQ:ATOS) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw started coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Atossa Genetics currently has a consensus rating of “Hold” and an average price target of $20.33.

Atossa Genetics Stock Up 7.3%

NASDAQ ATOS opened at $2.79 on Friday. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35. The business has a 50 day moving average price of $2.35 and a two-hundred day moving average price of $4.17. The stock has a market cap of $27.84 million, a PE ratio of -0.90 and a beta of 1.29.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.07. Sell-side analysts anticipate that Atossa Genetics will post -4.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors and hedge funds have recently made changes to their positions in the business. &PARTNERS acquired a new stake in shares of Atossa Genetics during the fourth quarter worth approximately $25,000. Hudson Bay Capital Management LP bought a new stake in shares of Atossa Genetics in the second quarter worth $26,000. JPMorgan Chase & Co. raised its holdings in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares in the last quarter. Bank of America Corp DE raised its holdings in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after acquiring an additional 144,412 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.